Ozempic vs Mounjaro for Type 2 Diabetes: A1C, Weight, and Side Effects Compared

By Dr. Blane Jackson, DDS, MBA · Reviewed 2026

Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are once-weekly injectables approved for type 2 diabetes. They lower A1C and produce meaningful weight loss in most patients. The mechanisms overlap but are not identical, and the head-to-head data favors tirzepatide on both A1C and weight at the higher doses. Here is how they actually compare in clinical use.

Mechanism: GLP-1 vs dual GIP/GLP-1

Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone glucagon-like peptide-1, which increases glucose-dependent insulin release, slows gastric emptying, suppresses glucagon, and reduces appetite.

Tirzepatide is a dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. Adding GIP activity to GLP-1 appears to amplify the insulin-secretory and weight effects without proportionally increasing GI side effects.

The practical implication: tirzepatide's mechanism produces, on average, somewhat larger reductions in A1C and weight at maximum doses. The two drugs are not interchangeable on a unit basis — they have different titration schedules.

Head-to-head efficacy (SURPASS-2)

SURPASS-2 was the pivotal 40-week trial randomizing 1,879 adults with type 2 diabetes on metformin to tirzepatide 5/10/15 mg or semaglutide 1 mg weekly.

Higher Ozempic doses (2 mg, available since 2022) close part of the A1C gap and bring weight loss closer to ~6–8 kg, but tirzepatide 15 mg still produces the largest average reductions across direct and indirect comparisons.

Dosing and titration

Both start low and escalate to manage GI tolerability.

• Ozempic: 0.25 mg weekly × 4 weeks → 0.5 mg → 1 mg → (optional) 2 mg, with at least 4 weeks at each step before escalating.
• Mounjaro: 2.5 mg weekly × 4 weeks → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, again with 4-week minimums.

Either can be paused or down-titrated for severe nausea. The 2.5 mg Mounjaro dose is a starting dose only and is not intended for maintenance.

Side effects

The profiles are similar; both are gut-mediated drugs.

• Nausea — 17–22% of patients during titration on either drug. Usually mild, improves within 2–4 weeks at a steady dose.
• Diarrhea — 12–18%.
• Constipation — 6–9%.
• Vomiting — 5–10%, slightly more frequent on tirzepatide at higher doses.
• Decreased appetite — expected effect, not technically an adverse event.
• Injection-site reactions — uncommon, usually mild.

Less common but more serious: pancreatitis, gallbladder disease (cholecystitis, cholelithiasis), and gastroparesis-like symptoms in a small subset. Both have a boxed warning for thyroid C-cell tumors based on rodent data; contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2.

Cardiovascular and kidney outcomes

Semaglutide has long-term cardiovascular outcomes data: in SUSTAIN-6, it reduced major adverse cardiovascular events (MACE) by about 26% versus placebo in high-risk patients with type 2 diabetes. The SELECT trial extended this CV benefit to non-diabetic patients with obesity.

Tirzepatide's dedicated CV outcomes trial (SURPASS-CVOT) reported in 2024 that tirzepatide is non-inferior to dulaglutide for MACE in T2D, with reassuring safety. Long-term kidney outcomes data for tirzepatide is still maturing; FLOW (semaglutide in CKD) showed a 24% reduction in kidney disease progression and death.

How to choose

Practical decision factors:

• A1C-focused: If your A1C is well above target (>9%) and weight is also a goal, Mounjaro has larger average reductions at top doses.
• Established CV disease: Semaglutide has the longer, more specific evidence base for MACE reduction and CKD progression. Reasonable to prefer it for patients with prior MI, stroke, or CKD.
• Insurance coverage: The cheaper-to-the-patient option after rebates and prior auth often wins. Mounjaro is more expensive list price; coverage varies.
• Tolerability: Either is acceptable. Patients who fail Ozempic for GI reasons sometimes tolerate Mounjaro and vice versa; the response is individual.
• History of pancreatitis or biliary disease: Be cautious with both; consider a non-GLP-1 alternative (SGLT2 inhibitor or others).
• Personal/family history of medullary thyroid cancer or MEN 2: Contraindicated.

What to monitor

• A1C every 3 months during titration.
• Weight at each visit; expect ongoing slow loss for up to 18 months.
• Symptoms of pancreatitis (severe persistent abdominal pain radiating to back) — stop and evaluate.
• Diabetic retinopathy screening at baseline and as scheduled; rapid glucose improvement can transiently worsen retinopathy.
• Kidney function (eGFR) annually or per guideline.
• Hypoglycemia risk is low as monotherapy but higher when combined with sulfonylureas or insulin — those doses often need to be reduced.

Frequently asked questions

Which lowers A1C more, Ozempic or Mounjaro?

Mounjaro at 10–15 mg produces the largest A1C reductions in head-to-head data (around -2.2 to -2.3 percentage points versus -1.86 for Ozempic 1 mg over 40 weeks). Both are highly effective; the difference matters most when starting A1C is well above target.

How much weight do people typically lose?

Average 5–6 kg on Ozempic 1 mg and 9–11 kg on Mounjaro 10–15 mg at 40 weeks. With longer treatment and the obesity-dose products (Wegovy, Zepbound), losses continue to ~15% and ~22% of body weight respectively. Individual response varies.

Are the side effects different?

Profiles are broadly similar — mostly transient GI symptoms during dose escalation. Vomiting may be slightly more common with Mounjaro at top doses; both share the thyroid C-cell warning and the pancreatitis/gallbladder cautions.

Will insurance cover them?

For type 2 diabetes, both are commonly covered by commercial and Medicare Part D plans, usually with prior authorization. Coverage for weight loss alone (no diabetes) is far more restricted and usually requires the obesity-indicated brand (Wegovy or Zepbound).

Can I switch from Ozempic to Mounjaro?

Yes, with a physician. Mounjaro is restarted at 2.5 mg even after prior GLP-1 exposure and then re-titrated. Expect a brief return of GI side effects.